Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in A msterdam; evidence for harm reduction? AS de Vos, JJ van der Helm, A Matser, M Prins, MEE Kretzschmar Addiction 108 (6), 1070-1081, 2013 | 91 | 2013 |
Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? AS de Vos, M Prins, MEE Kretzschmar Addiction 110 (6), 975-983, 2015 | 55 | 2015 |
Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands DK van Santen, AS de Vos, A Matser, SB Willemse, K Lindenburg, ... PloS one 11 (10), e0163488, 2016 | 53 | 2016 |
Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling: life span of infected cells, viral generation time, and basic reproductive … CL Althaus, AS De Vos, RJ De Boer Journal of virology 83 (15), 7659-7667, 2009 | 53 | 2009 |
Cost‐effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands AS de Vos, MP Janssen, HL Zaaijer, BM Hogema Transfusion 57 (2), 258-266, 2017 | 49 | 2017 |
Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users AS de Vos, JJ van der Helm, M Prins, ME Kretzschmar Epidemics 4 (2), 57-67, 2012 | 32 | 2012 |
Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models WA Stolk, JM Prada, ME Smith, P Kontoroupis, AS De Vos, P Touloupou, ... Clinical infectious diseases 66 (Supplement_4), S260-S266, 2018 | 28 | 2018 |
Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection AS De Vos, MEE Kretzschmar Mathematical biosciences 258, 11-18, 2014 | 26 | 2014 |
Impact of hepatitis E virus testing on the safety of blood components in Germany–results of a simulation study C Kamp, J Blümel, SA Baylis, I Bekeredjian‐Ding, M Chudy, M Heiden, ... Vox Sanguinis 113 (8), 811-813, 2018 | 24 | 2018 |
The effect of assortative mixing on stability of low helminth transmission levels and on the impact of mass drug administration: Model explorations for onchocerciasis AS de Vos, WA Stolk, SJ de Vlas, LE Coffeng PLoS Neglected Tropical Diseases 12 (10), e0006624, 2018 | 19 | 2018 |
The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users AS De Vos, MEE Kretzschmar Journal of theoretical biology 333, 126-134, 2013 | 19 | 2013 |
Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status DK Van Santen, JJ van der Helm, BPX Grady, AS de Vos, ... Aids 28 (17), 2589-2599, 2014 | 17 | 2014 |
Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS) N van Geel, L Depaepe, V Vandaele, L Mertens, J Van Causenbroeck, ... Journal of the European Academy of Dermatology and Venereology 36 (8), 1334-1341, 2022 | 15 | 2022 |
Treatment as prevention among injecting drug users; extrapolating from the Amsterdam cohort study AS de Vos, M Prins, RA Coutinho, JJ van der Helm, MEE Kretzschmar AIDS 28 (6), 911-918, 2014 | 11 | 2014 |
Bioenergetics, overcompensation, and the source–sink status of marine reserves D Claessen, AS de Vos, AM de Roos Canadian Journal of Fisheries and Aquatic Sciences 66 (7), 1059-1071, 2009 | 11 | 2009 |
A novel approach to detect test‐seeking behaviour in the blood donor population: making the invisible visible AS De Vos, RW Lieshout‐Krikke, E Slot, EA Cator, MP Janssen Vox Sanguinis 111 (3), 274-280, 2016 | 9 | 2016 |
The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages AS de Vos, WA Stolk, LE Coffeng, SJ de Vlas PLoS Neglected Tropical Diseases 15 (5), e0009011, 2021 | 6 | 2021 |
Understanding MRSA clonal competition within a UK hospital; the possible importance of density dependence AS de Vos, SJ De Vlas, JA Lindsay, MEE Kretzschmar, GM Knight Epidemics 37, 100511, 2021 | 5 | 2021 |
Markers of epidemiological success of methicillin-resistant Staphylococcus aureus isolates in European populations VO Baede, A Gupta, GM Knight, LM Schouls, K Laing, M Tavakol, ... Clinical Microbiology and Infection 29 (9), 1166-1173, 2023 | 4 | 2023 |
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: evidence for harm reduction? AS De Vos, JJ Van Der Helm, M Prins, MEE Kretzschmar Journal of the International AIDS Society 15, 78-78, 2012 | 4 | 2012 |